A novel method for the labeling and rapid separation of morphine, morphine-3-beta-Dglucuronide (M3G) and morphine-6-beta-D-glucuronide (M6G) in human urine employing a new boronic acid functionalized squarylium dye (SQ-BA3) and capillary electrophoresis with laser induced fluorescence detection (CE-LIF) is described. The spectrochemical properties, solution stability, pH range, and mechanisms for interactions with morphine and its metabolites were first established for SQ-BA3, followed by optimization of an on-column labeling procedure and CE-LIF method. SQ-BA3 itself was shown to be unstable and weakly fluorescent in aqueous buffers due to aggregate formation. However, SQ-BA3 showed a relative stability and dramatic increase in fluorescence intensity upon the addition of morphine, M3G, and M6G. Because of the low background fluorescence of this dye, on-column labeling was feasible, leading to a simple and rapid analytical method with the potential for clinical applications. Separations 2016, 3, 1 2 of 13
Introduction
Morphine is an opioid analgesic drug used for the treatment of moderate to severe pain. The primary metabolism pathway of morphine is by way of glucuronidation, where glucuronic acid is added at the 3-or 6-carbon of the molecule through UDP-glucuronosyltransferase-2B7 enzyme (UGT2B7) action in the liver, leading to formation of morphine-3-beta-D-glucuronide (M3G) and morphine-6-beta-D-glucuronide (M6G) [1] . M6G has been shown to exhibit activity at the µ-opioid receptor with a potency surpassing that of morphine, while M3G has no analgesic activity [2, 3] . While there is some indication that M3G might be responsible for the side effects felt after treatment [4] , other studies suggest that it is a functional antagonist of morphine and M6G [5] . Normorphine is another minor inactive metabolite and represents 5% of the initial dosage [6] . There is also evidence of a diglucuronide species, morphine-3,6-diglucuronide; however, the presence of this metabolite has only been documented in urine [7] . A 4.00 × 10 −4 M stock solution of SQ-BA3 was prepared by weighing out an appropriate amount of solid dye and dissolving this in DMF, dimethylformamide (Fisher Scientific, Fair Lawn, NJ, USA). The dye stock solution was stored in the dark at 4 °C, under which conditions it was stable for several months or longer. For this reason, all dye solutions were stored this way. A working solution of the dye was prepared by further dilution of the stock solution in DMF to a concentration of 1.00 × 10 −4 M just before use. Aliquots of this working solution were added to the appropriate buffer to serve as the background electrolyte (BGE) solution for CE studies. However, the final dye concentration was 1.00 × 10 −6 M for spectral studies and up to 5.00 × 10 −6 M for CE optimization studies.
Morphine, M3G and M6G standards (1 mg/mL in methanol) were used as received from Cerilliant (Round Rock, TX, USA). Morphine and M6G samples were stored at −10 °C and M3G was stored at 4 °C when not in use. Working solutions of drug standards for spectral and CE-LIF studies were prepared by dilution of the certified analytical standards with MilliQ distilled, deionized water (Millipore, Bedford, MA, USA) to the desired concentration of 5.00 × 10 −4 M just before use.
Buffers for spectral and CE-LIF studies were prepared by dissolving the appropriate quantity of reagent citric acid (Sigma Aldrich, St. Louis, MO, USA), tris (hydroxymethyl) aminomethane (AMRESCO, Solon, OH, USA) or ammonium dihydrogen phosphate (JMC, Royston, Hertfordshire, UK) in MilliQ distilled, deionized water prior to pH adjustment by the addition of 1 M NH4OH or 1 M HCl (Fisher Scientific, Pittsburgh, PA, USA). For some CE-LIF studies, phytic acid sodium salt (Sigma Aldrich, St. Louis, MO, USA) was added to the separation buffer to a concentration of 10 mM. All buffers were stored in high density polyethylene plastic bottles at room temperature for 1-2 weeks, and were filtered through 0.20 µm nylon syringe filters (VWR International, Houston, TX, USA) prior to use.
For spectral studies, drug-dye solution mixtures were prepared by adding 5.00 µL of the 1.00 × 10 −4 M solution of SQ-BA3 to a 500 µL quartz cuvettes. Some volumes of morphine, M3G and M6G working stock solution were then added to this aliquot of dye, along with sufficient buffer to achieve the final desired concentrations of both drugs and dye. The final volume for all solutions was 500 µL and the total organic solvent content in aqueous buffer solutions was kept below 10% (v/v).
Human Urine Sample Preparation
Normal human urine samples were obtained from Fisher Scientific (Pittsburgh, PA, USA) and were certified to be drug-and disease-free. Urine samples were kept frozen (−20 °C) before use, and were then stored at 4 °C between uses. For CE-LIF studies, urine samples were prepared by centrifugation at 500 rpm for 5 min using a 100-K molecular weight cutoff centrifugal Nanosep device (Pall Life Science, Ann Arbor, MI, USA) to remove large proteins. Filtered urine samples were then diluted 1:10 in high purity water before spiking with morphine, M3G and M6G standards to achieve the desired concentration of the drug or metabolite in urine. Final concentrations ranged from 3.50 × 10 −4 M-1.75 × 10 −3 M for morphine, 2.50 × 10 −4 M-1.25 × 10 −3 M for M3G, and 1.00 × 10 −3 M-1.75 × 10 −3 M for M6G. A 4.00ˆ10´4 M stock solution of SQ-BA3 was prepared by weighing out an appropriate amount of solid dye and dissolving this in DMF, dimethylformamide (Fisher Scientific, Fair Lawn, NJ, USA). The dye stock solution was stored in the dark at 4˝C, under which conditions it was stable for several months or longer. For this reason, all dye solutions were stored this way. A working solution of the dye was prepared by further dilution of the stock solution in DMF to a concentration of 1.00ˆ10´4 M just before use. Aliquots of this working solution were added to the appropriate buffer to serve as the background electrolyte (BGE) solution for CE studies. However, the final dye concentration was 1.00ˆ10´6 M for spectral studies and up to 5.00ˆ10´6 M for CE optimization studies.
Morphine, M3G and M6G standards (1 mg/mL in methanol) were used as received from Cerilliant (Round Rock, TX, USA). Morphine and M6G samples were stored at´10˝C and M3G was stored at 4˝C when not in use. Working solutions of drug standards for spectral and CE-LIF studies were prepared by dilution of the certified analytical standards with MilliQ distilled, deionized water (Millipore, Bedford, MA, USA) to the desired concentration of 5.00ˆ10´4 M just before use.
Buffers for spectral and CE-LIF studies were prepared by dissolving the appropriate quantity of reagent citric acid (Sigma Aldrich, St. Louis, MO, USA), tris (hydroxymethyl) aminomethane (AMRESCO, Solon, OH, USA) or ammonium dihydrogen phosphate (JMC, Royston, Hertfordshire, UK) in MilliQ distilled, deionized water prior to pH adjustment by the addition of 1 M NH 4 OH or 1 M HCl (Fisher Scientific, Pittsburgh, PA, USA). For some CE-LIF studies, phytic acid sodium salt (Sigma Aldrich, St. Louis, MO, USA) was added to the separation buffer to a concentration of 10 mM. All buffers were stored in high density polyethylene plastic bottles at room temperature for 1-2 weeks, and were filtered through 0.20 µm nylon syringe filters (VWR International, Houston, TX, USA) prior to use.
For spectral studies, drug-dye solution mixtures were prepared by adding 5.00 µL of the 1.00ˆ10´4 M solution of SQ-BA3 to a 500 µL quartz cuvettes. Some volumes of morphine, M3G and M6G working stock solution were then added to this aliquot of dye, along with sufficient buffer to achieve the final desired concentrations of both drugs and dye. The final volume for all solutions was 500 µL and the total organic solvent content in aqueous buffer solutions was kept below 10% (v/v).
Normal human urine samples were obtained from Fisher Scientific (Pittsburgh, PA, USA) and were certified to be drug-and disease-free. Urine samples were kept frozen (´20˝C) before use, and were then stored at 4˝C between uses. For CE-LIF studies, urine samples were prepared by centrifugation at 500 rpm for 5 min using a 100-K molecular weight cutoff centrifugal Nanosep device (Pall Life Science, Ann Arbor, MI, USA) to remove large proteins. Filtered urine samples were then diluted 1:10 in high purity water before spiking with morphine, M3G and M6G standards to achieve the desired concentration of the drug or metabolite in urine. Final concentrations ranged from 3.50ˆ10´4 M-1.75ˆ10´3 M for morphine, 2.50ˆ10´4 M-1.25ˆ10´3 M for M3G, and 1.00ˆ10´3 M-1.75ˆ10´3 M for M6G.
Instrumentation
CE-LIF studies were conducted using a Beckman Coulter P/ACE MDQ capillary electrophoresis instrument (Beckman Coulter, Brea, CA, USA) equipped with an external LIF detector module with a 635 nm diode laser (2.5 mW; Oz Optics, Ottawa, ON, Canada) and a 655 nm emission band-pass filter. Uncoated fused-silica capillary (Polymicro Technologies, Phoenix, AZ, USA) was employed for all separations, with optimized dimensions of 50 µm (ID)ˆ365 µm (OD)ˆ70 cm (total length)ˆ60 cm (effective length, inlet-to-detector). Each new length of capillary was conditioned by sequential pressure flushes (at 20 psi) with water (20 min), 1 M sodium hydroxide (20 min), water (20 min), and finally separation buffer (30 min). Prior to sample analysis at the start of each day, the capillary was subjected to a similar conditioning cycle, but pressure flushes were reduced to 10 min (water, 1 M NaOH, water) and 20 min (separation buffer). Between each run, the capillary was pressure flushed with water and buffer for 1 min and 2 min, respectively. Samples were injected by pressure at 5 psi for 10 s, and analyses were conducted using an applied separation voltage of 30 kV. The temperature of the capillary, buffer, and sample were held constant at 25˝C.
Fluorescence spectra were recorded using a Perkin-Elmer Luminescence Spectrometer (Shelton, CT, USA). Excitation and emission slit widths were 10 nm; the excitation wavelength (as specified in Table 1 ) was selected according to the wavelength of maximum absorbance for the sample or solution under consideration; and the emission wavelength range was scanned from 640 nm to 800 nm at a rate 250 nm/min. Fluorescence spectra of the free dye and mixtures of the dye with morphine (or morphine metabolites) were measured using a 1-cm, semi-micro (500 µL) quartz cuvette (Perkin-Elmer). Table 1 . Absorbance (λex) and fluorescence (λem) properties for boronic acid functionalized squarylium dye (SQ-BA3) (1.00ˆ10´6 M) with and without added morphine, morphine-3-beta-D-glucuronide (M3G), and morphine-6-beta-D-glucuronide (M6G) (5.00ˆ10´4 M) in dimethylformamide (DMF) and various aqueous buffer systems (25 mM). Absorbance studies were conducted over a scan range of 500-800 nm with an integration time of 0.5 s and an interval of 1 nm using a Hewlett Packard HP8453 UV/Vis spectrometer (Waldbronn, Germany) and a 1-cm semi-micro 500 µL quartz cuvette (Perkin-Elmer).
Solvent or Buffer

SQ-BA3 Alone
Results and Discussion
Spectral Properties of SQ-BA3 Alone and with Morphine, M3G, and M6G
Spectral properties of the novel squarylium dye SQ-BA3 were determined under various solution conditions in order to assess its suitability as a fluorescent probe for morphine and its glucuronide metabolites. The absorbance maximum for SQ-BA3 alone in aqueous buffer systems was slightly blue-shifted relative to the dye's response in DMF. Broad absorbance bands and hypsochromic shifts attributable to the formation of water-soluble dye aggregates have been reported by others [33, 34] , and this result for SQ-BA3 is also in agreement with the spectral behavior previously observed in our laboratory for SQ-BA [31] . According to Figure 2 , SQ-BA3 showed a sharp band at 550-680 nm with an intense maximum absorption at 631 nm as shown in Figure 2a (most likely due to soluble monomer) in DMF solvent, while a broadened band at around 500-750 nm was blue shifted by 12 nm (at 619 nm) with much lower absorption value of the free squarylium dye aggregates in ammonium phosphate buffer as seen in Figure 2b . This blue shift observed for the dye alone in aqueous buffer relative to the dye alone in DMF suggests that the aggregates in aqueous solution are H-type (parallel) as opposed to J-type (head-to-tail), as described by Fukuda and Nakahara [35] . An H-type aggregate would be formed by association of the terminal, pendant ethyl and methyl groups on one SQ-BA3 molecule with those on another SQ-BA3 molecule, which is more plausible than their association with the hydrophilic boronic acid group on another molecule of the dye (which would characterize a J-type aggregate). However, the absorbance was slightly enhanced after addition of M3G, morphine and M6G with maximum absorption at 622, 621 and 623 nm, repectively (Figure 2c -e).
Chromatography 2016, 3, 1 5 of 13 glucuronide metabolites. The absorbance maximum for SQ-BA3 alone in aqueous buffer systems was slightly blue-shifted relative to the dye's response in DMF. Broad absorbance bands and hypsochromic shifts attributable to the formation of water-soluble dye aggregates have been reported by others [33, 34] , and this result for SQ-BA3 is also in agreement with the spectral behavior previously observed in our laboratory for SQ-BA [31] . According to Figure 2 , SQ-BA3 showed a sharp band at 550-680 nm with an intense maximum absorption at 631 nm as shown in Figure 2a (most likely due to soluble monomer) in DMF solvent, while a broadened band at around 500-750 nm was blue shifted by12 nm (at 619 nm) with much lower absorption value of the free squarylium dye aggregates in ammonium phosphate buffer as seen in Figure 2b . This blue shift observed for the dye alone in aqueous buffer relative to the dye alone in DMF suggests that the aggregates in aqueous solution are H-type (parallel) as opposed to J-type (head-to-tail), as described by Fukuda and Nakahara [35] . An H-type aggregate would be formed by association of the terminal, pendant ethyl and methyl groups on one SQ-BA3 molecule with those on another SQ-BA3 molecule, which is more plausible than their association with the hydrophilic boronic acid group on another molecule of the dye (which would characterize a J-type aggregate). However, the absorbance was slightly enhanced after addition of M3G, morphine and M6G with maximum absorption at 622, 621 and 623 nm, repectively (Figure 2c -e). Dye concentration and aggregation studies were performed only at pH 7.50, which was deemed to be the optimal for the dye itself as reported by Ouchi et al. [32] . Increasing the dye concentration from 5.00 × 10 −7 M to 4.00 × 10 −6 M did not appear to affect the aggregation state of the dye, since this resulted in a linear increase in absorbance according to Beer's Law (see Supplementary Data, Figure S1 ). However, fluorescence emission of the dye was saturated above a concentration of 1.00 × 10 −6 M (see Supplementary Data, Figure S2 ). Dye aggregation may be responsible for such saturation.
A summary of the absorbance (λabs) and fluorescence emission (λem) properties of the dye, with and without added morphine, M3G, and M6G in DMF and various aqueous buffer systems is presented in Table 1 . Dye concentration and aggregation studies were performed only at pH 7.50, which was deemed to be the optimal for the dye itself as reported by Ouchi et al. [32] . Increasing the dye concentration from 5.00ˆ10´7 M to 4.00ˆ10´6 M did not appear to affect the aggregation state of the dye, since this resulted in a linear increase in absorbance according to Beer's Law (see Supplementary Data, Figure S1 ). However, fluorescence emission of the dye was saturated above a concentration of 1.00ˆ10´6 M (see Supplementary Data, Figure S2 ). Dye aggregation may be responsible for such saturation.
A summary of the absorbance (λabs) and fluorescence emission (λem) properties of the dye, with and without added morphine, M3G, and M6G in DMF and various aqueous buffer systems is presented in Table 1 .
According to Table 1 , a large Stokes shift (of approximately 40 nm) was observed for SQ-BA3 (with or without added analyte) in each of the solvent systems tested. Such a shift provides good analytical discrimination between excitation and emission signals, thus allowing for more sensitive detection. The fluorescence background arising due to a 1.00ˆ10´6 M solution of SQ-BA3 alone was greatest under basic pH conditions, which parallels the effect of solution pH on the fluorescence of a boronic acid functionalized squaryium dye SQ-BA in prior studies from our lab [20] . However, even under these conditions, the observed enhancement in fluorescence upon the addition of high concentrations of morphine analytes (5.00ˆ10´4 M) suggests that this functionalized squarylium dye (or some variant of the dye) may, indeed, be suitable for pharmaceutical detection or screening.
The greatest fluorescence enhancements (calculated as the difference between emission intensities in the presence and absence of analyte divided by the emission intensity of dye alone) were observed for SQ-BA3 with added morphine, M3G or M6G under basic pH conditions (for example, in ammonium phosphate at pH 9.50, as illustrated in Figure 3 , and Table 1 where the best fluorescence enhancements were highlighted in bold). Furthermore, the concentration of buffering species, however, had no impact on fluorescence enhancements. For example, increasing the concentration of ammonium phosphate (pH 9.50) from 25 mM to 100 mM did not yield any further enhancement of the fluorescence emission of the SQ-BA3 dye. According to Table 1 , a large Stokes shift (of approximately 40 nm) was observed for SQ-BA3 (with or without added analyte) in each of the solvent systems tested. Such a shift provides good analytical discrimination between excitation and emission signals, thus allowing for more sensitive detection. The fluorescence background arising due to a 1.00 × 10 −6 M solution of SQ-BA3 alone was greatest under basic pH conditions, which parallels the effect of solution pH on the fluorescence of a boronic acid functionalized squaryium dye SQ-BA in prior studies from our lab [20] . However, even under these conditions, the observed enhancement in fluorescence upon the addition of high concentrations of morphine analytes (5.00 × 10 −4 M) suggests that this functionalized squarylium dye (or some variant of the dye) may, indeed, be suitable for pharmaceutical detection or screening.
The greatest fluorescence enhancements (calculated as the difference between emission intensities in the presence and absence of analyte divided by the emission intensity of dye alone) were observed for SQ-BA3 with added morphine, M3G or M6G under basic pH conditions (for example, in ammonium phosphate at pH 9.50, as illustrated in Figure 3 , and Table 1 where the best fluorescence enhancements were highlighted in bold). Furthermore, the concentration of buffering species, however, had no impact on fluorescence enhancements. For example, increasing the concentration of ammonium phosphate (pH 9.50) from 25 mM to 100 mM did not yield any further enhancement of the fluorescence emission of the SQ-BA3 dye. According to the table, it was noted that the fluorescence enhancement observed for SQ-BA3 with added M6G (+6.20%) was significantly lower than with added M3G (+23.45%) in 25 mM ammonium phosphate buffer (pH 9.50), despite the fact that these two metabolites are isomers of one another and so might be expected to respond similarly in the presence of the dye. Chromatographic behavior of these isomers has indicated a difference in their relative polarities, with M3G demonstrating more polar character than M6G [36] . Thus, the more polar character of M3G seems to favor interaction with the SQ-BA3 dye, perhaps through enhanced dipole-dipole or hydrogen bonding interactions. With its pKa value near 8 [37] , morphine would exist largely in its neutral or negatively charged state in the ammonium phosphate buffer (pH 9.50), which may favor its electrostatic interaction with the SQ-BA3 dye.
The absence of a significant shift in the wavelength of maximum absorbance of the metabolitedye complex (621 nm) and the morphine-dye complex (619 nm) relative to the free dye (618 nm) in phosphate buffer (pH 9.50) suggests that the dye is not necessarily forming a covalent complex with the analyte via boronate esterification. Such a reaction would be expected to result in the disaggregation of the dye in aqueous solution, which would, in turn, be expected to result in the According to the table, it was noted that the fluorescence enhancement observed for SQ-BA3 with added M6G (+6.20%) was significantly lower than with added M3G (+23.45%) in 25 mM ammonium phosphate buffer (pH 9.50), despite the fact that these two metabolites are isomers of one another and so might be expected to respond similarly in the presence of the dye. Chromatographic behavior of these isomers has indicated a difference in their relative polarities, with M3G demonstrating more polar character than M6G [36] . Thus, the more polar character of M3G seems to favor interaction with the SQ-BA3 dye, perhaps through enhanced dipole-dipole or hydrogen bonding interactions. With its pKa value near 8 [37] , morphine would exist largely in its neutral or negatively charged state in the ammonium phosphate buffer (pH 9.50), which may favor its electrostatic interaction with the SQ-BA3 dye.
The absence of a significant shift in the wavelength of maximum absorbance of the metabolite-dye complex (621 nm) and the morphine-dye complex (619 nm) relative to the free dye (618 nm) in phosphate buffer (pH 9.50) suggests that the dye is not necessarily forming a covalent complex with the analyte via boronate esterification. Such a reaction would be expected to result in the disaggregation of the dye in aqueous solution, which would, in turn, be expected to result in the absorbance maximum of the dye-analyte complex more closely resembling that of the free dye in its disaggregated state, as it exists in DMF (λabs = 631 nm). Since neither morphine nor its glucuronide metabolites possess cis-diol functionalities, it is not surprising that these analytes lack specific covalent interactions with the SQ-BA3 dye. Even in the absence of specific covalent interactions, evidence of dye-analyte interaction is clearly provided by the significant change in the emission of the dye-analyte complex relative to the emission of the free dye as monitored by fluorimetry.
Stability of SQ-BA3 Solutions
Since the solubility and stability of many fluorescent dyes in aqueous solution is poor [38] , we prepared a concentrated stock solution of SQ-BA3 in DMF prior to mixing it with analyte standards or samples. The stability of the dye alone and of mixtures of the dye with opioid analytes diluted in 25 mM ammonium citrate (pH 3.50), 25 mM Tris-HCL (pH 7.50), or 25 mM ammonium phosphate (pH 9.50 and 11.30) buffers was investigated over a one-week period, during which time the samples were stored in quartz cuvettes. Previous work with the related, unfunctionalized dye SQ-BA revealed that adsorption of the dye onto glass or polypropylene vessel walls during storage could result in decreased fluorescence emission over time [31] . The stability of aqueous solutions of SQ-BA3 (1.00ˆ10´6 M) alone and with added morphine, M3G, or M6G (5.00ˆ10´4 M) was monitored by fluorimetry. Despite using only quartz wares, which minimizes adsorption of the dye on its walls, the fluorescence signal of SQ-BA3 alone decreased by 50% within the first 24 h after dilution with 25 mM ammonium citrate buffer (pH 3.50) or with 25 mM Tris-HCL buffer (pH 7.50). Beyond this initial 24-h period, the signal remained stable (with no further decrease in fluorescence emission) for up to one week. However, the addition of morphine or M3G to these SQ-BA3 solutions resulted in the stabilization of the fluorescence emission (no reduction in RFU) for up to 72 h, whereas the addition of M6G resulted in the same decrease in fluorescence (50%) observed for the dye alone over this same period of time. These observations would suggest that both morphine and M3G interact more strongly with SQ-BA3 than does M6G (in agreement with spectral studies, vide supra), and that such interactions to form dye-analyte complex can prevent fluorescence degradation by offering some protection for the dye against hydrolysis, aggregation, etc.
Under basic solution conditions, the dye alone was less stable than under acidic and neutral solution conditions. The fluorescence signal of SQ-BA3 alone rapidly degraded to just 50% of its original value within the first 6 h after dilution with 25 mM ammonium phosphate buffer, and to just 10% of its original value within 48 h. In this basic buffer, the addition of M3G offered no further stabilization of the fluorescence signal, and the addition of morphine or M3G provided less of a stabilizing influence than in acidic and neutral buffers where the fluorescence signal was degraded to 60% and 30% of its original value after 6 h and 48 h, respectively.
These stability studies confirmed the relatively weak interaction of M6G with SQ-BA3 compared to interactions of morphine and M3G with the dye. Additionally, these studies served to inform optimal solution and sample handling procedures for the analytical studies to follow. It should be noted that, due to the dye instability, and, in particular for the case of on-column labeling of morphine analytes, the calibration curves were recorded using dye-buffer mixtures prepared freshly between runs to avoid decreased absorbance readings due to dye degradation.
Optimization of CE-LIF Methods for Morphine and Its Metabolites
Solution conditions leading to optimal fluorescence enhancement for SQ-BA3 with the opioid analytes being considered herein were then transposed to a CE-LIF platform to serve as a starting point for analytical separation method development. High efficiency CE-based separation methods are ideal for the determination of closely related analytes, such as the isobaric glucuronide metabolites of morphine. As previously established in our laboratory [17] , a number of different background electrolytes at pH 9.50 led to baseline resolution of morphine, M3G, and M6G by CE, and although ammonium borate was found to be ideal for the separation of analytes in our prior work, ammonium phosphate was also found to be suitable, and so in the present work, we employed phosphate buffers rather than borate buffers for CE-LIF studies to eliminate any possible competitive reactions with the boronic acid functionalized SQ-BA3 dye. Additionally, the wide buffer capacity range of ammonium phosphate enables us to determine the most suitable pH for separation. Furthermore, the chosen ammonium phosphate buffer was to be used as a part of an on-column labeling scheme for CE-LIF analysis in the present work, whereby a fixed concentration of SQ-BA3 (1.00ˆ10´6 M) was added to the separation buffer to provide for fluorescent tagging of the analytes during separation, thus eliminating the need for more complicated sample derivatization steps prior to analysis. The benefits of on-column fluorescent labeling schemes for CE-LIF are well established, including reduced sample handling, reduced total analysis time, and enhanced signal [30] . Additional parameters to be optimized for this chosen buffer system for on-column labeling and analysis of morphine, M3G, and M6G included pH, concentration of background electrolyte and dye, and the utility of buffer additives (specifically, phytic acid), while CE parameters to be optimized included applied voltage and capillary dimensions.
Whereas it was found that 25 mM ammonium phosphate buffer adjusted to pH 9.50 provided the greatest fluorescence enhancement for 1.00ˆ10´6 M SQ-BA3 with 5.00ˆ10´4 morphine, M3G, or M6G (see Section 3.1), these buffer conditions did not permit the resolution of a mixture of opioid analyte standards when employed for CE-LIF analysis with on-column labeling. Using this buffer system, morphine, M3G, and M6G standards comigrated at 4.16 min (data not shown). Buffer pH was adjusted incrementally from 8.00 to 10.50 with no improvement in separation. A detailed pH study conducted previously for CE-MS studies [17] revealed that baseline resolution of morphine, M3G, and M6G could be achieved with an ammonium phosphate buffer over a very narrow pH range only (from 8.70-10.30). The fact that buffers within this range did not yield baseline separation of opioid analyte standards in the present work can be attributed to the presence of SQ-BA3 in the buffer (as required for on-column labeling in CE-LIF) in the present work. The presence of the dye will affect the ionic strength of the buffer and, hence, the electroosmotic mobility. In addition, it will affect the electrophoretic mobility of the analytes by virtue of its association with the analytes to form fluorescent complexes for detection by LIF. As such, buffer conditions suitable for CE-MS analysis may not be directly transferrable to CE-LIF systems.
To improve resolution, we explored the use of the buffer additive, phytic acid. Phytic acid contains six phosphate groups bound to a hexane ring, with pKa values ranging from 1.90 to 9.50 [39] . It is a nontoxic, naturally occuring phosphate source, which has been shown to improve CE-based separations by ion-pairing interactions [40] . Phytic acid concentrations in the running buffer were varied from 0 to 20 mM. Morphine, M3G and M6G were not resolved with phytic acid concentrations less than 5 mM. Complete resolution was achieved with 10 mM phytic acid but only when the buffer pH was increased to 10.50. Resolution was retained at higher concentrations of phytic acid, but migration times were increased, so 10 mM phytic acid was deemed optimal. A representative electropherogram with peaks for M6G, morphine, and M3G at 2.56, 3.15 and 3.79 min, respectively, is shown in Figure 4a . The identity of each peak was verified by spiking a known amount of each analyte into the mixture.
Other aspects of the buffer composition, including buffer concentration and concentration of added SQ-BA3, were studied to determine their effect on the CE-LIF determination of morphine, M3G and M6G. Increasing the buffer concentration from 10-100 mM has the effect of decreasing the rate of electroosmotic flow, which was seen as a net increase in migration time for the analytes in this study. Upon consideration of not only migration time and resolution, but also peak shape and signal intensity, these studies indicated an optimal buffer concentration of 25 mM ammonium phosphate (with 10 mM phytic acid buffer additive). The concentration of dye added to the separation buffer to facilitate on-column labeling can affect not only the sensitivity of the method but also the overall rate of electroosmotic flow and hence, the resolution of the method. Optimization of dye concentration must, therefore, be conducted for any given assay. This was done by keeping the amount of morphine Separations 2016, 3, 1 9 of 13 (5.00ˆ10´4 M) injected onto the column constant while varying the concentration of dye in the run buffer. When the SQ-BA3 dye concentration was doubled from 1.00ˆ10´6 M to 2.00ˆ10´6 M, the peak area of the complex did not increase. However, when the dye concentration was further increased to 5.00ˆ10´6 M, the peak area of the dye-morphine complex decreased (see Supplementary Data, Figure S3 ). This effect may have been due to increased background or greater adsorption of dye to the inner wall of the capillary, thus reducing analyte signal. Thus, 1.00ˆ10´6 M dye in the optimized separation buffer (25 mM ammonium phosphate at pH 10.5, with 10 mM phytic acid) provided the best compromise between background signal from free dye and fluorescence enhancement of analyte-bound dye. This effect may have been due to increased background or greater adsorption of dye to the inner wall of the capillary, thus reducing analyte signal. Thus, 1.00 × 10 −6 M dye in the optimized separation buffer (25 mM ammonium phosphate at pH 10.5, with 10 mM phytic acid) provided the best compromise between background signal from free dye and fluorescence enhancement of analytebound dye. Having thus optimized CE buffer conditions for separation and detection of morphine and its metabolites, we set out to optimize CE operational parameters including separation voltage and capillary dimensions. Although baseline resolution of the morphine, M3G, and M6G standards was nominally achieved for applied separation voltages ranging from 10-30 kV (see Figure S4 ), the peak shape was optimal and the migration time was minimized at 30 kV, and so this separation voltage was adopted for subsequent studies. Additionally, the effect of capillary inner diameter (ID) was studied. Only the 50 µm ID uncoated fused silica capillary led to both baseline resolution and good peak shape for morphine, M3G and M6G, whereas a 25 µm ID capillary yielded baseline resolution but poor peak shape, and a 75 µm ID capillary yielded good peak shape but poor resolution.
Employing all of these optimized conditions, CE-LIF calibration curves were established for on-column labeling of morphine, M3G, and M6G standards with SQ-BA3. The calibration results are Having thus optimized CE buffer conditions for separation and detection of morphine and its metabolites, we set out to optimize CE operational parameters including separation voltage and capillary dimensions. Although baseline resolution of the morphine, M3G, and M6G standards was nominally achieved for applied separation voltages ranging from 10-30 kV (see Figure S4 ), the peak shape was optimal and the migration time was minimized at 30 kV, and so this separation voltage was adopted for subsequent studies. Additionally, the effect of capillary inner diameter (ID) was studied.
Only the 50 µm ID uncoated fused silica capillary led to both baseline resolution and good peak shape for morphine, M3G and M6G, whereas a 25 µm ID capillary yielded baseline resolution but poor peak shape, and a 75 µm ID capillary yielded good peak shape but poor resolution.
Employing all of these optimized conditions, CE-LIF calibration curves were established for on-column labeling of morphine, M3G, and M6G standards with SQ-BA3. The calibration results are summarized in Table 2 , which highlights a linear increase in peak area as a function of analyte concentration with excellent correlation coefficients (R2 > 0.994) for each analyte (see also Figure S5 ). 
CE-LIF Analysis of Morphine and Its Metabolites in Human Urine Samples
Normal human urine samples with added morphine and morphine glucuronide metabolite standards were prepared according to the procedure described earlier (see Section 2.2) and were subjected to the optimized CE-LIF analysis with on-column labeling with SQ-BA3. Recognizing the sensitivity limitations of the method, initial urine sample dilutions of just 1:1 and 1:5 with water were conducted. However, morphine and M3G co-eluted in samples thus prepared (as seen in Figure 4b ).
The complete separation of all three analytes could be achieved using a 10-fold dilution of the urine samples with water (as seen in Figure 4c ) with slight delay of migration time may be due to the urine matrix which indeed decreases the electroosmotic flow inside the capillary. Whereas previous CE-MS studies in our laboratory utilized the running buffer as the diluent for urine-based samples containing morphine and its metabolites [17] , such sample preparation in buffer for CE-LIF studies herein did not lead to resolution of the three analytes of interest while dilution in water achieved the required separation. As such, figures of merit for morphine, M3G and M6G in a normal human urine matrix prepared by a 10-fold dilution with water are summarized in Table 2 (compared to figures of merit for comparable analyte mixtures in water only). In addition, relative standard deviations for both water and diluted urine matrices showed a highly precise method with minimal error bars and variations for all calibration curve concentrations as presented in Table 2 and Figures S5, S6 . Although sensitivities achieved by this CE-LIF method are not as high as for CE-MS [17] , which showed LODs in the order of 10´6 and 10´7, CE-MS method requires more analysis time whereas CE-LIF is more cost-efficient screening option with the potential to develop selective squarylium dye probes with reactivity towards a single class of analytes. Thus, a demonstration of the feasibility of using SQ-BA3 as a fluorescent, on-column label for the CE-LIF analysis of small drug molecules and their metabolites in a clinical sample matrix such as urine, or at least in the pharmaceutical field, was pursued.
Conclusions
A novel method for the rapid separation and detection of morphine, M3G, and M6G in human urine by CE-LIF was established. On-column labeling of morphine and its metabolites was done by utilizing a new boronic acid functionalized squarylium dye, SQ-BA3. This dye has been shown to possess useful characteristics for sensing morphine and its metabolites, including the demonstration of fluorescence enhancements for morphine, M3G and M6G under a variety of solution conditions. Spectroscopic and electrophoretic studies provided evidence that the boronic acid functionalized dye does not interact with the opioid analytes by way of specific boronate ester formation, but rather, by electrostatic, dipole, and H-bond types of interactions. Such interactions are sufficient to maintain the integrity of the dye-analyte complex as it migrates in CE, according to its net electrophoretic mobility, past the LIF detector. Optimized CE-LIF conditions included a 25 mM ammonium phosphate separation buffer (pH 10.50) containing 10 mM phytic acid to aid separation and 1.00ˆ10´6 M SQ-BA3 to facilitate on-column labeling. This method provided sufficient resolution to distinguish between isobaric glucuronide metabolites of morphine. Minimal sample preparation, which included just a molecular weight cutoff filtration and a 10-fold dilution of urine samples with water, was required prior to CE-LIF analysis of urine samples containing opioid standards, making this an attractive tool for drug detection. By combining the high resolving power of CE with the sensitivity of LIF detection and the convenience of on-column labeling, applications for novel squarylium dyes as probes for new drugs of interest are expected to grow.
